A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1015

Enrollment

INDUSTRY

Sponsor class

Stopped Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Methotrexate
DRUG: ocrelizumab
DRUG: Placebo

Sponsor

Genentech, Inc.

Collaborators

[object Object]